Gut microbiota-derived tryptamine and phenethylamine impair insulin sensitivity in metabolic syndrome and irritable bowel syndrome.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
17 08 2023
Historique:
received: 15 02 2023
accepted: 31 07 2023
medline: 21 8 2023
pubmed: 18 8 2023
entrez: 17 8 2023
Statut: epublish

Résumé

The incidence of metabolic syndrome is significantly higher in patients with irritable bowel syndrome (IBS), but the mechanisms involved remain unclear. Gut microbiota is causatively linked with the development of both metabolic dysfunctions and gastrointestinal disorders, thus gut dysbiosis in IBS may contribute to the development of metabolic syndrome. Here, we show that human gut bacterium Ruminococcus gnavus-derived tryptamine and phenethylamine play a pathogenic role in gut dysbiosis-induced insulin resistance in type 2 diabetes (T2D) and IBS. We show levels of R. gnavus, tryptamine, and phenethylamine are positively associated with insulin resistance in T2D patients and IBS patients. Monoassociation of R. gnavus impairs insulin sensitivity and glucose control in germ-free mice. Mechanistically, treatment of R. gnavus-derived metabolites tryptamine and phenethylamine directly impair insulin signaling in major metabolic tissues of healthy mice and monkeys and this effect is mediated by the trace amine-associated receptor 1 (TAAR1)-extracellular signal-regulated kinase (ERK) signaling axis. Our findings suggest a causal role for tryptamine/phenethylamine-producers in the development of insulin resistance, provide molecular mechanisms for the increased prevalence of metabolic syndrome in IBS, and highlight the TAAR1 signaling axis as a potential therapeutic target for the management of metabolic syndrome induced by gut dysbiosis.

Identifiants

pubmed: 37591886
doi: 10.1038/s41467-023-40552-y
pii: 10.1038/s41467-023-40552-y
pmc: PMC10435514
doi:

Substances chimiques

phenethylamine 327C7L2BXQ
tryptamine 422ZU9N5TV
Phenethylamines 0
Tryptamines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

4986

Informations de copyright

© 2023. Springer Nature Limited.

Références

Gut Microbes. 2022 Jan-Dec;14(1):2128605
pubmed: 36217238
J Clin Invest. 2020 Jan 2;130(1):438-450
pubmed: 31815740
Am J Med Sci. 2009 Aug;338(2):116-9
pubmed: 19561452
Gerontology. 2016;62(6):611-617
pubmed: 27120471
FEMS Microbiol Lett. 2015 Jan;362(2):1-6
pubmed: 25670703
Mol Endocrinol. 2003 Mar;17(3):487-97
pubmed: 12554784
Cell Host Microbe. 2014 Oct 8;16(4):495-503
pubmed: 25263219
Diabetes. 2003 Mar;52(3):634-41
pubmed: 12606502
Lancet Diabetes Endocrinol. 2022 Jul;10(7):481-483
pubmed: 35662399
Gut Microbes. 2020 Nov 1;11(6):1774-1789
pubmed: 32529941
Nature. 2020 Nov;587(7834):448-454
pubmed: 33149306
ISME J. 2022 Apr;16(4):983-996
pubmed: 34750528
Br J Pharmacol. 2006 Dec;149(8):967-78
pubmed: 17088868
Cell Metab. 2021 Apr 6;33(4):791-803.e7
pubmed: 33338411
Nat Rev Gastroenterol Hepatol. 2014 Aug;11(8):497-505
pubmed: 24751910
Cell Host Microbe. 2023 Jan 11;31(1):33-44.e5
pubmed: 36495868
Front Pharmacol. 2021 Nov 22;12:784231
pubmed: 34880765
ILAR J. 2006;47(3):259-71
pubmed: 16804200
Mol Pharmacol. 2009 Aug;76(2):229-35
pubmed: 19389919
Am J Physiol Endocrinol Metab. 2016 Apr 15;310(8):E643-E651
pubmed: 26860984
Nature. 2017 Nov 30;551(7682):648-652
pubmed: 29168502
Mol Cell Proteomics. 2014 Oct;13(10):2593-603
pubmed: 24997997
J Diabetes Sci Technol. 2012 May 01;6(3):503-14
pubmed: 22768880
Diabetes Obes Metab. 2019 May;21(5):1111-1120
pubmed: 30575251
Trends Endocrinol Metab. 2020 Nov;31(11):818-834
pubmed: 32284282
Nat Commun. 2019 Oct 3;10(1):4505
pubmed: 31582752
Drug Metab Dispos. 2015 Oct;43(10):1536-43
pubmed: 25873348
Int J Mol Sci. 2021 Nov 27;22(23):
pubmed: 34884651
Neurosci Biobehav Rev. 2021 Jan;120:537-541
pubmed: 33031817
BMJ. 1995 Feb 18;310(6977):446
pubmed: 7873953
Front Pharmacol. 2021 Dec 09;12:788795
pubmed: 34975485
Endocrinology. 2007 Jun;148(6):2955-62
pubmed: 17317777
BMJ Open Sci. 2020 Jul 20;4(1):e100115
pubmed: 34095516
J Neurogastroenterol Motil. 2022 Apr 30;28(2):173-184
pubmed: 35189599
Cell Host Microbe. 2018 Jun 13;23(6):775-785.e5
pubmed: 29902441
Curr Diab Rep. 2011 Jun;11(3):160-6
pubmed: 21431855
Nutrients. 2015 Apr 16;7(4):2930-46
pubmed: 25894657
Cell. 2020 Sep 17;182(6):1460-1473.e17
pubmed: 32916129
Nat Rev Endocrinol. 2019 May;15(5):261-273
pubmed: 30670819
J Biol Chem. 2019 Mar 22;294(12):4401-4411
pubmed: 30670596
Science. 2018 Mar 9;359(6380):1151-1156
pubmed: 29590046

Auteurs

Lixiang Zhai (L)

Centre for Chinese Herbal Medicine Drug Development, Hong Kong Baptist University, Hong Kong SAR, China.
School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR, China.

Haitao Xiao (H)

School of Pharmaceutical Sciences, Health Science Center, Shenzhen University, Shenzhen, China.

Chengyuan Lin (C)

Centre for Chinese Herbal Medicine Drug Development, Hong Kong Baptist University, Hong Kong SAR, China.

Hoi Leong Xavier Wong (HLX)

School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR, China.

Yan Y Lam (YY)

Centre for Chinese Herbal Medicine Drug Development, Hong Kong Baptist University, Hong Kong SAR, China.

Mengxue Gong (M)

State Key Laboratory of Microbial Metabolism and Ministry of Education Key Laboratory of Systems Biomedicine, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, China.

Guojun Wu (G)

Department of Biochemistry and Microbiology and New Jersey Institute for Food, Nutrition, and Healthy. School of Environmental and Biological Sciences, Rutgers University, New Brunswick, NJ, 08901, USA.

Ziwan Ning (Z)

Centre for Chinese Herbal Medicine Drug Development, Hong Kong Baptist University, Hong Kong SAR, China.
School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR, China.

Chunhua Huang (C)

Centre for Chinese Herbal Medicine Drug Development, Hong Kong Baptist University, Hong Kong SAR, China.
School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR, China.

Yijing Zhang (Y)

School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR, China.

Chao Yang (C)

Department of Computer Science, Hong Kong Baptist University, Hong Kong SAR, China.

Jingyuan Luo (J)

Centre for Chinese Herbal Medicine Drug Development, Hong Kong Baptist University, Hong Kong SAR, China.
School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR, China.

Lu Zhang (L)

Department of Computer Science, Hong Kong Baptist University, Hong Kong SAR, China.

Ling Zhao (L)

Academy of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.

Chenhong Zhang (C)

State Key Laboratory of Microbial Metabolism and Ministry of Education Key Laboratory of Systems Biomedicine, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, China.

Johnson Yiu-Nam Lau (JY)

School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR, China.

Aiping Lu (A)

School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR, China.

Lok-Ting Lau (LT)

School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR, China.

Wei Jia (W)

Phenome Research Centre, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR, China. weijia1@hkbu.edu.hk.
Shanghai Key Laboratory of Diabetes Mellitus and Center for Translational Medicine, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China. weijia1@hkbu.edu.hk.

Liping Zhao (L)

Department of Biochemistry and Microbiology and New Jersey Institute for Food, Nutrition, and Healthy. School of Environmental and Biological Sciences, Rutgers University, New Brunswick, NJ, 08901, USA. liping.zhao@rugters.edu.

Zhao-Xiang Bian (ZX)

Centre for Chinese Herbal Medicine Drug Development, Hong Kong Baptist University, Hong Kong SAR, China. bianzxiang@gmail.com.
School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR, China. bianzxiang@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH